This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2021.
Company Filing History:
1 out of 331 
1 out of 5,383 
1 out of 1,853 
Years Active: 2021
Title: Mickaël Menand: Innovator in Cyclodextrin Technology
Introduction
Mickaël Menand is a notable inventor based in Alfortville, France. He has made significant contributions to the field of cyclodextrin technology, particularly in the pharmaceutical sector. His innovative work has led to the development of a unique patent that showcases his expertise and creativity.
Latest Patents
Mickaël Menand holds a patent for a "Capped cyclodextrin-hydrophobic moiety conjugate, cyclodextrin supramolecular polymer, and cyclodextrin-siRNA complex and method of synthesis thereof." This invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, which is essential for creating a supramolecular polymer and a siRNA-cyclodextrin complex. The capped cyclodextrin-hydrophobic moiety conjugate comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker. This invention has various applications, particularly in the pharmaceutical field, and represents a significant advancement in drug delivery systems.
Career Highlights
Throughout his career, Mickaël Menand has worked with prestigious institutions such as Sorbonne Université and the Centre National De La Recherche Scientifique. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Mickaël has collaborated with notable colleagues, including Matthieu Sollogoub and Vincent Calvez. These partnerships have further enriched his research and innovation efforts.
Conclusion
Mickaël Menand is a distinguished inventor whose work in cyclodextrin technology has the potential to revolutionize pharmaceutical applications. His patent and collaborations reflect his commitment to advancing scientific knowledge and improving drug delivery systems.